Category
Blog
-
2023
-
FDA Approves Second Interchangeable Insulin Product, Rezvoglar (insulin glargine-aglr)
-
Regeneron, CytomX announce bispecific therapeutics for cancer collab
-
Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation
-
Nona and Dragonfly enter HCAb-based drug discovery partnership
-
FDA Grants Breakthrough Therapy Status to Iveric Bio’s Zimura for AMD
-
New CRISPR-based tool inserts large DNA sequences at desired sites in cells
-
EC grants approval for AbbVie’s Skyrizi to treat Crohn’s disease
-
Senators Introduce New Bill to Promote Research and Access to MDMA, Psilocybin
-
Chemotherapy could increase disease susceptibility in future generations
-
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy